Mutational signatures among young-onset testicular cancers

BMC Medical Genomics

Table 1 Prevalence of gene mutations

Gene	20–29	30–39	> 40	Total	p-value (20–29 vs. > 40)	p-value (30–39 vs. > 40)	p-value (continuous age)
KIT	7 (12%)	8 (15%)	7 (33%)	22 (16%)	0.25	0.093	0.20
KRAS	4 (7%)	7 (13%)	3 (14%)	14 (10%)	0.65	0.99	0.55
NRAS	2 (3%)	2 (4%)	2 (10%)	6 (4%)	0.65	0.19	0.47
PIK3CD	1 (2%)	3 (6%)	1 (5%)	5 (4%)	0.62	0.84	0.66
PIK3CA	1 (2%)	2 (4%)	0 (0%)	3 (2%)	NA	NA	0.95

Prevalence of somatic mutations in genes of interest among testicular tumors diagnosed at ages 20–29 (n = 59), 30–39 (n = 54), age 40 or older (n = 21), and at any age (n = 134). Entries are number (proportion) of cases in each age of onset group with each gene present. Differences in gene mutations by age at onset groups were tested using a logistic regression model * indicates statistical significance at a .05 level

ISSN: 1755-8794